NEW YORK, Feb 1 – Bolstered by solid revenues on its custom genomics programs, Incyte posted increased fourth quarter revenues Thursday, and forecasted a continuing growth curve throughout 2001.

Incyte expects to post revenues of between $220 and $240 million in the coming year, said John Vuko, Incyte’s Chief Financial officer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.